EUVIMEDEUVIMED entdecken
Crossref

Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans

Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y Hsu, Joseph Ware, Laurent Salphati

Drug Metabolism and Disposition · 2023

DOI: 10.1124/dmd.122.001096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023. Verfasst von Shuguang Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics (S.M., S.C., W.Z., J.P., X.D., B.D., L.S.) and Department of Clinical Pharmacology (S.S., J.Y.H., …. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Body Fluids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesBody FluidsHumansRatsDogsAnimalsPhosphoinositide-3 Kinase InhibitorsFecesAdministration, OralImidazolesOxazepines

Substanzen

Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase Inhibitors2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-…ImidazolesOxazepines

Autor:innen und Institutionen

  • Department of Drug Metabolism and Pharmacokinetics (S.M., S.C., W.Z., J.P., X.D., B.D., L.S.) and Department of Clinical Pharmacology (S.S., J.Y.H., J.W.), Genentech, Inc., South San Francisco, California; and XenoBioti…

Zitieren

APA

Ma, S., Cho, S., Sahasranaman, S., Zhao, W., Pang, J., Ding, X., Dean, B., Wang, B., Hsu, J. Y., Ware, J., & Salphati, L. (2023). Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.122.001096

Vancouver

Ma S, Cho S, Sahasranaman S, Zhao W, Pang J, Ding X, et al. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans. Drug Metabolism and Disposition. 2023. doi:10.1124/dmd.122.001096

BibTeX
@article{Ma2023,
  author = {Ma, Shuguang and Cho, Sungjoon and Sahasranaman, Srikumar and Zhao, Weiping and Pang, Jodie and Ding, Xiao and Dean, Brian and Wang, Bin and Hsu, Jerry Y and Ware, Joseph and Salphati, Laurent},
  title = {Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans},
  journal = {Drug Metabolism and Disposition},
  year = {2023},
  doi = {10.1124/dmd.122.001096}
}
Kostenlos starten →